REVELATION BIOSCIENCES, INC. (REVB) research
REVELATION BIOSCIENCES, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.76
- As of
REVELATION BIOSCIENCES, INC. (REVB): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-19.
As of . Source: SEC EDGAR filings for REVB. Method and limitations.
Share the REVB intelligence card
See the full REVB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for REVB on one page. Preview it with sample data, then open it live with a free account.
Preview the REVB dossierActive signals for REVB
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in REVB
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 131.0% - EPS $-2.71 vs $-1.173 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 54.3% - EPS $-28.04 vs $-18.1764 estimate
- mediumEARNINGS_MISS
Q3-2025: Missed consensus by 30.0% - EPS $-7.08 vs $-5.4468 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 541.5% - EPS $-23.95 vs $-3.7332 estimate
FREE, NO ACCOUNT
Every signal on REVB, as it fires
You are seeing 5 of 6 signals recorded on REVB since 2026-05-26.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in REVB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 76135L804 · 2026Q2 | $40K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, REVB
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
REVB against its peers
REVB's return on equity of -100.6% ranks in the 71st percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | REVB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 131000 | n/a | 11 |
| Gross margin | n/a | 80.6% | n/a | 7 |
| Operating margin | n/a | -5143.5% | n/a | 10 |
| Net margin | n/a | -4911.4% | n/a | 10 |
| Return on equity | -100.6% | -483.3% | 71 | 11 |
Peers (17): APVO, JUNS, BRTX, GOVX, JAGX, MBIO, GLMD, VIVS, CVKD, HCWB, ERNA, SILO, ADTX, AAGH, CLDI, APTOF, BCAB. Left out: ADXN (period gap), MLEC (period gap), BVAXF (no annual filing), XRTX (no annual filing), ELAB (no annual filing), LSBCF (period gap), LABT (no annual filing), VCNX (period gap). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (REVB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more REVB signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to REVBand get the insider, 13F, options, and confluence read in one view.